The steep tariff on foreign-made drugs is an aggressive tactic to compel pharmaceutical companies to bring manufacturing back to the US. It aims to solve two critical problems: reducing strategic dependency on adversaries like China and rebuilding domestic manufacturing jobs.

The nature of biopharma M&A changed dramatically in a year. After a period with no deals over $5 billion, there are now seven or eight such transactions, reflecting a pivot by large pharma to acquire de-risked assets with large market potential to offset looming patent expirations.

Large pharmaceutical companies face losing up to 50% of their revenues by 2030 due to the largest patent expiration wave in history. To survive, they will be forced to acquire innovation from the biotechnology sector, fueling a sustained M&A cycle for years to come.

To achieve Most Favored Nation (MFN) drug pricing, the administration paired HHS negotiators with the Commerce Secretary. While one team negotiated terms, the Commerce Secretary acted as the "hammer," holding a credible threat of crippling tariffs over pharmaceutical companies that primarily manufacture overseas. This forced compliance.

After intense scenario analysis during initial tariff announcements, life sciences companies have developed templates to manage trade policy risks. This preparedness has demoted tariffs from a major strategic driver to a manageable operational factor, allowing M&A to proceed with less hesitation.

The proposed pharma tariffs include a key loophole: the Secretary of Commerce can exempt any product by designating it a "specialty drug." This subjective clause opens the door for political influence, cronyism, and intense lobbying to secure exemptions, adding a layer of political risk for companies.

With patent cliffs looming and mature assets acquired, large pharmaceutical companies are increasingly paying billion-dollar prices for early-stage and even preclinical companies. This marks a significant strategic shift in M&A towards accepting higher risk for earlier innovation.

The current M&A landscape is defined by a valuation disparity where smaller companies trade at a discount to larger ones. This creates a clear strategic incentive for large corporations to drive growth by acquiring smaller, more affordable competitors.

Pharmaceutical companies are engaging in lengthy negotiations with US biotech startups while simultaneously exploring cheaper, faster assets in China. This creates negotiation leverage and puts downward pressure on valuations and deal terms for US-based innovators.